IP Library Granted Patent US 8,669,241
Granted Patent B2
US 8,669,241 · App. 12/591,784 · Granted Mar 11, 2014

Ophthalmic composition

Inventors: Yasuko Matsumura (Osaka, JP); Mariyo Kato (Osaka, JP)
Assignee: Rohto Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,669,241
App. No.
12/591,784
Granted
Mar 11, 2014
Kind
B2
Abstract

The ophthalmic composition of the invention comprises (A) lecithin and (B) at least one refrigerant selected from the group consisting of camphor, borneol, eucalyptus oil, and bergamot oil. In the ophthalmic composition, the odor of lecithin is efficiently masked by the refrigerant. The odor of lecithin after aging is also masked by the refrigerant. Since the refrigerant is volatile, the concentration thereof in a composition tends to gradually decrease. It is surprising that the odor of lecithin after aging can nevertheless be masked.

Claims (23)

1. An ophthalmic composition comprising:

(A) lecithin at a concentration of 0.05-5 w/v %,

(B) at least one refrigerant selected from the group consisting of camphor and borneol at a concentration of 0.001-0.05 w/v %,

(C) at least one alcohol selected from the group consisting of glycerin, propylene glycol, polyethylene glycol, sorbitol, xylitol, mannitol, ethanol, propanol, butanol, and pentanol at a concentration of 0.05-5 w/v %, and

(D) vegetable oil at a concentration of 0.01-1 w/v %

with the proviso that the composition excludes chlorobutanol.

2. The ophthalmic composition according to claim 1 , wherein the vegetable oil is sesame oil or castor oil.

3. The ophthalmic composition according to claim 1 , wherein the alcohol is at least one kind selected from the group consisting of glycerin, propylene glycol, and ethanol.

4. A method for inhibiting the increase of the odor of lecithin caused by aging, the method comprising a step of mixing (A), (B), (C) and (D) as defined in claim 1 to obtain an ophthalmic composition,

wherein the obtained composition comprises (A) at a concentration of 0.05-5 w/v %, (B) at a concentration of 0.001-0.05 w/v %, (C) at a concentration of 0.05-5 w/v %, and (I)) at a concentration of 0.01-1 w/v %,

with the proviso that the composition excludes chlorobutanol,

wherein the increase of the odor of lecithin caused by aging is inhibited.

5. A method for reducing the cytotoxicity of borneol, comprising a step of mixing (A), (B), (C) and (D) as defined in claim 1 to obtain an ophthalmic composition,

wherein the refrigerant is borneol,

wherein the obtained composition comprises (A) at a concentration of 0.05-5 w/v %, (B) at a concentration of 0.001-0.05 w/v %, (C) at a concentration of 0.05-5 w/v %, and (D) at a concentration of 0.01-1 w/v %,

with the proviso that the composition excludes chlorobutanol, and

wherein the cytotoxicity of borneol is reduced.

6. A method for inhibiting oxidation of lecithin, comprising a step of mixing (A), (B), (C) and (D) as defined in claim 1 to obtain an ophthalmic composition, wherein the obtained composition comprises (A) at a concentration of 0.05-5 w/v %, (B) at a concentration of 0.001-0.05 w/v %, (C) at a concentration of 0.05-5 w/v %, and (D) at a concentration of 0.01-1 w/v %,

with the proviso that the composition excludes chlorobutanol,

wherein the oxidation of lecithin is inhibited.

7. A method for improving eyestrain, comprising a step of administering the composition as defined in claim 1 , to an eye of a human, wherein eyestrain is improved.

8. A method for treating dry eye, comprising a step of administering the composition as defined in claim 1 to an eye of a human, wherein dry eye is treated.

9. A method for stabilizing three-layer structure of tear, comprising a step of administering the composition as defined in claim 1 to an eye of a human, wherein three-layer structure of tear is stabilized.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2010
From: MATSUMURA, YASUKO; KATO, MARIYO
To: ROHTO PHARMACEUTICAL CO., LTD.
Reel/Frame 023856/0590 →
Priority Claims (2)
JP 2008-307957 · Dec 2, 2008 · national
JP 2009-215467 · Sep 17, 2009 · national
Continuity (2)
Provisional Application 61193547 · Dec 5, 2008
Related Publication 20100137252A1 · Jun 3, 2010